MX2021000281A - Composiciones y métodos relacionados con construcciones de dominio de unión a antígeno y fc modificadas genéticamente dirigidas a pd-l1. - Google Patents

Composiciones y métodos relacionados con construcciones de dominio de unión a antígeno y fc modificadas genéticamente dirigidas a pd-l1.

Info

Publication number
MX2021000281A
MX2021000281A MX2021000281A MX2021000281A MX2021000281A MX 2021000281 A MX2021000281 A MX 2021000281A MX 2021000281 A MX2021000281 A MX 2021000281A MX 2021000281 A MX2021000281 A MX 2021000281A MX 2021000281 A MX2021000281 A MX 2021000281A
Authority
MX
Mexico
Prior art keywords
antigen binding
binding domain
engineered
compositions
methods related
Prior art date
Application number
MX2021000281A
Other languages
English (en)
Spanish (es)
Inventor
Jonathan C Lansing
Daniel Ortiz
Anthony Manning
Laura Rutitzky
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of MX2021000281A publication Critical patent/MX2021000281A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2021000281A 2018-07-11 2019-07-11 Composiciones y métodos relacionados con construcciones de dominio de unión a antígeno y fc modificadas genéticamente dirigidas a pd-l1. MX2021000281A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862696711P 2018-07-11 2018-07-11
PCT/US2019/041306 WO2020014419A2 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1

Publications (1)

Publication Number Publication Date
MX2021000281A true MX2021000281A (es) 2021-11-12

Family

ID=69141681

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000281A MX2021000281A (es) 2018-07-11 2019-07-11 Composiciones y métodos relacionados con construcciones de dominio de unión a antígeno y fc modificadas genéticamente dirigidas a pd-l1.

Country Status (11)

Country Link
US (1) US20210147549A1 (https=)
EP (1) EP3820998A4 (https=)
JP (1) JP2021530989A (https=)
KR (1) KR20210044782A (https=)
CN (1) CN112996910A (https=)
AU (1) AU2019299935A1 (https=)
BR (1) BR112021000383A2 (https=)
CA (1) CA3106108A1 (https=)
IL (1) IL280038A (https=)
MX (1) MX2021000281A (https=)
WO (1) WO2020014419A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024219897A1 (ko) * 2023-04-21 2024-10-24 상트네어바이오사이언스 주식회사 두 개의 fab 도메인 및 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
EP4700047A1 (en) * 2023-04-21 2026-02-25 Centenaire Biosciences, Inc. Antigen-binding protein containing two fc domains and use thereof
CN117736329B (zh) * 2023-12-25 2024-11-12 华润生物医药有限公司 抗pd-1抗体及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101764096B1 (ko) * 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
SG11201405226TA (en) * 2012-03-08 2014-11-27 Crucell Holland Bv Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
EP4299595A3 (en) * 2014-05-02 2024-03-13 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
CN107405399B (zh) * 2015-01-02 2022-02-08 武田药品工业株式会社 针对血浆激肽释放酶和因子xii的双特异性抗体
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
MY193229A (en) * 2015-06-16 2022-09-26 Merck Patent GmbH Pd-l1 antagonist combination treatments
JP2018529719A (ja) * 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
EP3423572B1 (en) * 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
CA3007135A1 (en) * 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Novel anti-pd-l1 antibodies
DK3484514T3 (da) * 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
EP3507367A4 (en) * 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
US20190322767A1 (en) * 2016-12-23 2019-10-24 Innate Pharma Heterodimeric antigen binding proteins

Also Published As

Publication number Publication date
US20210147549A1 (en) 2021-05-20
CN112996910A (zh) 2021-06-18
WO2020014419A3 (en) 2020-02-20
JP2021530989A (ja) 2021-11-18
BR112021000383A2 (pt) 2021-04-06
EP3820998A2 (en) 2021-05-19
AU2019299935A1 (en) 2021-02-18
EP3820998A4 (en) 2022-04-27
WO2020014419A2 (en) 2020-01-16
CA3106108A1 (en) 2020-01-16
WO2020014419A8 (en) 2021-12-02
KR20210044782A (ko) 2021-04-23
IL280038A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
MX2021000306A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno y fc modificados genéticamente dirigidos a ctla-4.
MX2021000307A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc dirigidos a cd38 diseñados por ingeniería genética.
MX2023005201A (es) Composiciones de proteinas de fusion quimerica modificadas por ingenieria y metodos de uso de las mismas.
PH12019550147A1 (en) Engineered transferrin receptor binding polypeptides
PH12019501440A1 (en) Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
CR20200171A (es) Contorsbodies 2 + 1 biespecíficos
MX2022015823A (es) Receptores de antigenos quimerlcos basados en anticuerpos de dominio simple y metodos de uso de estos.
EP4299595A3 (en) Compositions and methods related to engineered fc constructs
TN2010000169A1 (en) Molecules and methods for modulating complement component
MX2018003689A (es) Proteinas de union a pd-1 y metodos para usarlas.
MX2017014699A (es) Polipeptidos novedosos.
NZ590668A (en) TNF-alpha ANTAGONIST MULTI-TARGET BINDING PROTEINS
MX2021000287A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
NZ740474A (en) Antigen receptors and uses thereof
MX2021000281A (es) Composiciones y métodos relacionados con construcciones de dominio de unión a antígeno y fc modificadas genéticamente dirigidas a pd-l1.
WO2020014429A3 (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4
WO2022197949A3 (en) Engineered chimeric fusion protein compositions and methods of use thereof
MX2021000280A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
MX2022003316A (es) Composiciones y métodos relacionados con constructos de fc-dominio de unión al antígeno diseñados por ingeniería dirigidos a cd38.
MX2021000288A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
MX2021000305A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
BR112022002761A2 (pt) Proteínas de ligação a 4-1bb e ox40 e composições e métodos relacionados, anticorpos contra 4-1bb, anticorpos contra ox40
HK40053035A (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1
HK40053032A (en) Compositions and methods related to engineered fc-antigen binding domain constructs
HK40053031A (en) Compositions and methods related to engineered fc-antigen binding domain constructs